Welcome to our dedicated page for Sigyn Therapeutics SEC filings (Ticker: SIGY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
When you follow a development-stage company like Sigyn Therapeutics, Inc., you’re not just scanning numbers—you’re tracking the science behind blood purification, the timeline to first-in-human studies, and every financing that keeps research moving. Our SEC Filings hub answers the natural questions investors type every day, from “Sigyn Therapeutics SEC filings explained simply” to “Sigyn Therapeutics insider trading Form 4 transactions.”
Start with the documents that matter most. The annual report 10-K details R&D spend, device regulatory pathways, and patent status—we provide a “Sigyn Therapeutics annual report 10-K simplified” summary so you can pinpoint key risks in minutes. Need quarter-to-quarter updates? Each “Sigyn Therapeutics quarterly earnings report 10-Q filing” comes with AI-generated trend tables and variance commentary. Material announcements—reverse stock splits, clinical agreements, FDA meetings—appear in real time under “Sigyn Therapeutics 8-K material events explained.”
- Instant alerts for “Sigyn Therapeutics Form 4 insider transactions real-time” so you never miss executive buying or selling.
- Contextual highlights that link R&D cost spikes to upcoming trials, answering “Sigyn Therapeutics earnings report filing analysis.”
- Clear breakdowns of “Sigyn Therapeutics proxy statement executive compensation” to see how management aligns rewards with milestones.
Behind the scenes, Stock Titan’s AI reads every exhibit, performs language sentiment, and converts technical jargon into plain English. Whether you’re understanding Sigyn Therapeutics SEC documents with AI, tracking “Sigyn Therapeutics executive stock transactions Form 4,” or preparing for the next financing round, our platform delivers the insight professionals need—without the 200-page slog.
Sigyn Therapeutics (SIGY) filed its Q3 2025 10‑Q, reporting continued losses and limited liquidity. The company posted a net loss of $578,503 for the quarter and $2,698,254 for the nine months ended September 30, 2025. Cash was $85,571 with total assets of $135,571, against total liabilities of $6,052,780, resulting in a stockholders’ deficit of $(5,917,209). The filing states substantial doubt about the company’s ability to continue as a going concern.
Sigyn had no revenue and funded operations through convertible debt and a Regulation D offering. In 2025 it sold 69 Units for $379,717 aggregate principal (cash received $345,197) and issued additional 2025 convertible notes, including variable‑price notes that created a $181,362 derivative liability. Key noteholders extended maturities to December 31, 2027 in exchange for original issue discounts totaling $737,786. An inducement to preferred holders resulted in a $845,901 expense.
The company is repositioning around CardioDialysis and filed a trademark to support the strategy shift. As of November 14, 2025, common shares outstanding were 1,605,377.
FAQ
What is the current stock price of Sigyn Therapeutics (SIGY)?
What is the market cap of Sigyn Therapeutics (SIGY)?
